FL lawmakers reserve $50M for Jackson Lab branch; Stratech gains $3M round; ASCO execs plead for funds to repair trial program;

 @FierceBiotech: This was part of the BIO 2010 gift bag--a stuffed E. Coli. What do I do with this? Picture | Follow @FierceBiotech 

 @JohnCFierce: Anybody want to play the cost game on pirfenidone if approved? I've seen ranges of $30-50k. So that means $65k, right? | Follow @JohnCFierce

> Florida may be within reach of yet another new biotech R&D coup. The state legislature has included $50 million to fund a new branch of the Maine-based Jackson Laboratory. The lab wants to devote work at the new institute to the development of new therapies. Story

> Stratatech, which is developing a human skin substitute, has closed a $3 million funding round. Report

> Japan's Santen Pharmaceutical will pay Clinical Data a $2 million upfront fee to kick off their partnership to develop new topical therapies for ophthalmic diseases. Story

> FDA staffers say that some of the data Questcor Pharmaceuticals has submitted to back its request to use Acthar gel to treat infantile spasms are somewhat unusual and difficult to interpret. Report

> Cempra Pharmaceuticals announced positive results from its Phase II clinical trial of the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic. Release

> DSM Biologics has struck a deal with Australian authorities to build a new mammalian biopharmaceutical manufacturing facility in Brisbane. Story

> Live from BIO 2010: A human face for the drug industry. Story

And Finally... Two top execs at the American Society of Clinical Oncology used a letter in the New York Times to call for more funds to repair the National Cancer Institute's clinical cancer research program. Letter

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.